Valneva Secures Up To $500M Non-Dilutive Debt Facility; Lowers FY25 Total Revenue Guidance From €180 Million - €190 Million To €165 Million - €180 Million

Author: Benzinga Newsdesk | October 06, 2025 11:38am

• New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business development
• Company adjusts 2025 financial guidance and provides key business updates

Saint-Herblain (France), October 6, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon Advisors, LP. An initial tranche of $215 million will be used to repay in full the Company's existing debt facility with Deerfield Management Company and OrbiMed, inclusive of associated fees and expenses. The remaining up to $285 million may be drawn in the future for potential business development subject to mutual agreement between the parties. The Agreement was executed today and the initial tranche is expected to be funded in the coming weeks.

Highlights of the new facility include:

• Lowered cost of capital: Improved financial terms, including more favorable fixed interest rate and lower prepayment and exit fees compared to previous debt facility
  
  
  
   
• Improved structure and flexibility: Converted from an amortizing structure to a more capital efficient bullet maturity after five years, with no financial covenants
  
  
  
   
• Access to non-dilutive growth capital: Additional tranche(s) may be drawn for purposes of future value creation through business development
  
  
  
   

This new facility significantly enhances Valneva's financial flexibility, as the Company will no longer be required to begin making amortization payments in 2026. This results in substantial cost savings over the coming years, ahead of anticipated revenues from Valneva's Lyme disease vaccine candidate, VLA15, subject to potential approval in 2027.

Posted In: PARIS:VLA VALN